Medicare Part D Coverage of Antiobesity Medications — Challenges and Uncertainty Ahead
New England Journal of Medicine · 16.03.2023 · 388 (11) · 961-963
DOI: 10.1056/nejmp2300516 ↗Kurz gefasst
Fachartikel in der Zeitschrift New England Journal of Medicine, erschienen am 16.03.2023. Verfasst von Khrysta Baig und 3 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Health Policy, Vanderbilt University School of Medicine, Nashville (K.B., S.B.D., A.A.L.), and the Department of Medicine, Uni…. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Interview with Dr. Ashley Leech on the potential implications of Medicare Part D covering medications for obesity treatment. (11:22)Download Medicare could soon be compelled to cover antiobesity medications, which intensifies the need to address questions of effectiveness and cost among its beneficiaries.
Autor:innen und Institutionen
- From the Department of Health Policy, Vanderbilt University School of Medicine, Nashville (K.B., S.B.D., A.A.L.), and the Department of Medicine, University of Chicago, Chicago (D.D.K.).
Zitieren
APA
Baig, K., Dusetzina, S. B., Kim, D. D., & Leech, A. A. (2023). Medicare Part D Coverage of Antiobesity Medications — Challenges and Uncertainty Ahead. New England Journal of Medicine, 388(11), 961-963. https://doi.org/10.1056/nejmp2300516
Vancouver
Baig K, Dusetzina SB, Kim DD, Leech AA. Medicare Part D Coverage of Antiobesity Medications — Challenges and Uncertainty Ahead. New England Journal of Medicine. 2023;388(11):961-963. doi:10.1056/nejmp2300516
BibTeX
@article{Baig2023,
author = {Baig, Khrysta and Dusetzina, Stacie B and Kim, David D and Leech, Ashley A},
title = {Medicare Part D Coverage of Antiobesity Medications — Challenges and Uncertainty Ahead},
journal = {New England Journal of Medicine},
year = {2023},
volume = {388},
number = {11},
pages = {961--963},
doi = {10.1056/nejmp2300516}
}
EUVIMED